Abstract 163P
Background
ERCC1 and ERCC2 are major enzymes involved in nucleotide excision repair (NER). Single nucleotide polymorphisms (SNPs) affect the mRNA level and stability resulting in an alteration in protein translation. ERCC1/2 SNPs potentially association with survival in various cancers but the data in CCA was limited.
Methods
We did a retrospective review and genomic DNA analysis from FFPE tissue of patients diagnosed locally advanced or metastatic CCA who received palliative chemotherapy. The target SNPs included ERCC1 C19007T, C8092A and ERCC2 C312T, A2251C.
Results
Genomic DNA analysis was done in 64 patients but only 54 patients received platinum-based chemotherapy were use in the survival analysis. The ERCC1 C19007T CT SNP had a trend to have better OS than wild-type (CC), 8.8 vs 6.3 months respectively, the HR was statistically significant in multivariate survival analysis (HR 0.47 (0.23-0.94), p = 0.032). The ERCC1 C8092A both homozygous (AA) and heterozygous (CA) SNPs had shorter OS compare with wild-type (CC), 6.2, 8.0 and 9.5 months respectively, there was a trend to statistically significant between CT and CC group HR 1.83 (0.96-3.51), p = 0.067. These findings also observe in response rate and disease control rate. Conversely, ERCC2 SNPs did not associate with the outcome.
Conclusions
ERCC1 C19007T and ERCC1 C8092A SNPs are associated with the overall survival but not the ERCC2 SNPs in cholangiocarcinoma patients receiving platinum-based chemotherapy. Longer survival is seen in ERCC1 C19007T heterozygous SNP (CT) but shorter in ERCC1 C8092A.
Clinical trial identification
Human Ethics Committee of Khon Kaen University (HE611254).
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract